Your participation in the study will help increase the knowledge and understanding of MAC lung disease to potentially benefit the broader MAC patient community.
You will not receive any payment for taking part in the study. You may receive:
Yes, there have been other clinical studies. This study treatment was previously tested in Phase 2 and Phase 3 trials. The study treatment was approved in patients for a different condition.
Once you have given your consent, the study doctor will discuss this with you and determine if you are eligible and able to continue using your current medications.
You are free to withdraw from the study at any time without giving a reason and without your medical care or rights being affected.
Not all MAC patients respond to currently available treatments. Therefore, there is a need to develop and find potential new treatments for people with MAC lung disease through clinical studies.
Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The company is dedicated to developing and bringing to market therapies that make a real difference in patients’ lives, while striving to understand and enhance the entire patient experience. Headquartered in the United States, Insmed is a rapidly growing company with more than 500 employees around the world.